Abstract 13242: Risk of Cardiovascular Events in Patients with Type 2 Diabetes Treated With Exenatide BID or Other Glucose-Lowering Therapies: A Retrospective Analysis of the LifeLinkTM Database
Introduction: Studies of agents that reduce hyperglycemia in patients (pts) with type 2 diabetes have shown differing effects on cardiovascular disease (CVD) outcomes.
Objectives: The primary study objective was to assess the relative incidence rate of first CVD events in a real world setting among pts with type 2 diabetes prescribed exenatide BID (Ex), a GLP-1 receptor agonist, compared to pts treated with glucose-lowering agent(s) other than exenatide (non-Ex): sulfonylureas (SU), metformin (MET), thiazolidinediones (TZDs), insulins (INS), or sitagliptin (SITA).
Methods: Analyses included pts in the LifeLinkTM database initiating a new prescription (Rx) for a glucose-lowering agent between June 1, 2005, and March 31, 2009, without an Rx for the same agent in the prior 9 months. Pts were followed until one of the following occurred: CVD event (acute myocardial infarction, stroke, or coronary revascularization procedure), insurance disenrollment, or study end. Intention to treat analyses of patient outcomes (CVD events and all-cause hospitalization), adjusted for differences in clinical and demographic characteristics, were compared using propensity-score-weighted methods.
Results: (Table, Figure) Ex pts were more likely than non-Ex pts (except SITA) to have indication of CVD (eg, hyperlipidemia, hypertension). Ex-treated pts were less likely to have a CVD event or hospitalization than SU-, TZD-, and INS-treated pts.
Conclusion: Exenatide treatment was associated with a lower risk of CVD-related events than treatment with SUs, TZDs, or INS.
- © 2010 by American Heart Association, Inc.